NMRA Neumora Therapeutics, Inc. - 8-K

Item 5.07

Submission of Matters to a Vote of Security Holders.

On May 27, 2026, Neumora Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 17, 2026 (the “Definitive Proxy Statement”). Only stockholders of record as of the close of business on April 7, 2026, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 182,688,076 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders and until their respective successor is elected and qualified or until their earlier death, resignation, disqualification or removal. The results of the vote were as follows:

Nominee

Votes For

Votes Withheld

Broker

Non-Votes

Paul L. Berns

126,617,746

6,076,577

25,026,919

Matthew Fust

125,242,046

7,452,277

25,026,919

David Piacquad

126,878,899

5,815,424

25,026,919

Proposal 2. The ratification of the selection by the audit committee of the board of directors of the Company (the “Board”) of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. The results of the vote were as follows:

Votes For

Votes Against

Abstentions

157,623,815

53,613

43,814

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

Proposal 3. The advisory vote on the compensation of the Company’s named executive officers. The results of the vote were as follows:

Votes For

Votes Against

Abstentions

Broker Non-Votes

131,998,871

420,917

274,535

25,026,919

Proposal 4. The advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results of the vote were as follows:

For One Year

For Two Years

For Three Years

Abstentions

Broker Non-Votes

124,682,414

23,968

7,948,592

39,349

25,026,919

In accordance with the recommendation of the Board and the voting results on this advisory proposal, the Company will hold an advisory vote to approve the named executive officer compensation every year.